|Description||Mirk-IN-1, a pyrido[2,3-d]pyrimidine derivative, has been found to be a DYRK1A/B inhibitor and probably have antitumor activity through influencing the accumulation and induce the DNA damage and apoptosis of Panc1 in tumor cells. IC50: 68±48/22±8 nM (Dyrk|
|Synonyms||Mirk-IN-1; CHEMBL3094448; SCHEMBL10446906; CQKBSRPVZZLCJE-UHFFFAOYSA-N; BDBM50444379; AKOS025147328; N-[2-chloro-5-[(3-chlorophenyl)methylcarbamoyl]phenyl]-2-methoxy-7-oxo-8H-pyrido[2,3-d]pyrimidine-6-carboxamide|
|Solubility||10 mM in DMSO|
|Application||Mirk-IN-1 has been found to be a DYRK1A/B inhibitor and probably have antitumor activity through influencing the accumulation and induce the DNA damage and apoptosis of Panc1 in tumor cells.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
GSK-626616 is a YAK3/DYRK3 kinase inhibitor. It is a chemoprotective agent for the potential treatment of chemotherapy-induced anaemia.
AZ191 is a cell-permeable azaindole that inhibits the serine/threonine kinase activity of DYRK1B (IC50 = 17 nM) with 5-fold and 110-fold selectivity against the...
Mirk-IN-1, a pyrido[2,3-d]pyrimidine derivative, has been found to be a DYRK1A/B inhibitor and probably have antitumor activity through influencing the accumula...